Glaucoma Implant Maker Glaukos Boosts IPO Target
Venture capital-backed Glaukos Corp. sweetened terms for its initial public offering Tuesday, setting its sights on roughly $100 million as the implantable glaucoma treatment developer looks to expand marketing, fund research...To view the full article, register now.
Already a subscriber? Click here to view full article